Financial Comparison: Revolutions Medical (OTCMKTS:RMCP) and PROCEPT BioRobotics (NASDAQ:PRCT)

PROCEPT BioRobotics (NASDAQ:PRCT) and Revolutions Medical (OTCMKTS:RMCP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Profitability

This table compares PROCEPT BioRobotics and Revolutions Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-58.73%	-37.85%	-26.20%
Revolutions Medical	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings for PROCEPT BioRobotics and Revolutions Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	0	0	7	0	3.00
Revolutions Medical	0	0	0	0	N/A

PROCEPT BioRobotics presently has a consensus target price of $78.17, indicating a potential upside of 5.63%. Given PROCEPT BioRobotics’ higher possible upside, equities research analysts clearly believe PROCEPT BioRobotics is more favorable than Revolutions Medical.

Earnings and Valuation

This table compares PROCEPT BioRobotics and Revolutions Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$176.58 million	21.55	-$105.90 million	($2.12)	-34.91
Revolutions Medical	N/A	N/A	N/A	N/A	N/A

Revolutions Medical has lower revenue, but higher earnings than PROCEPT BioRobotics.

Institutional and Insider Ownership

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 17.4% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 10.5% of Revolutions Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

PROCEPT BioRobotics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Revolutions Medical has a beta of -0.43, suggesting that its stock price is 143% less volatile than the S&P 500.

Summary

PROCEPT BioRobotics beats Revolutions Medical on 6 of the 9 factors compared between the two stocks.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

About Revolutions Medical

Revolutions Medical Corporation, a development stage company, is engaged in the design, development, and commercialization of auto retractable vacuum safety syringes in the United States and internationally. The company develops RevVac auto retractable vacuum safety syringe, which is designed to reduce accidental needle stick injuries and lower the spread of blood borne diseases. It is also developing a suite of magnetic resonance imaging software tools consisting of RevColor, Rev3D, RevDisplay, and RevScan that are designed to enhance general diagnostic confidence through education and research use. The company sells its products to acute care hospitals, alternate care facilities, doctors' offices, clinics, emergency centers, surgical centers, convalescent hospitals, veterans administration facilities, military organizations, public health facilities, and prisons through distributors. Revolutions Medical Corporation was founded in 1996 and is headquartered in Charleston, South Carolina.